Use of Materials Derived From Cattle in Human Food and Cosmetics
fda-food · Food and Drug Administration · Rule · Published 2005-09-07 · Effective 2005-10-07 · 70 FR 53063
Document
Document number
05-17693
Federal Register citation
70 FR 53063
CFR reference
21 CFR 189
Type
Rule
Action
Interim final rule and request for comments.
Category
fda-food
Sub-agency
Food and Drug Administration
Publication date
2005-09-07
Effective date
2005-10-07
HHS docket
Docket No. 2004N-0081
Abstract
The Food and Drug Administration (FDA) is amending the interim final rule on use of materials derived from cattle in human food and cosmetics published in the Federal Register of July 14, 2004. In the July 14, 2004, interim final rule, FDA designated certain materials from cattle, including the entire small intestine, as "prohibited cattle materials" and banned the use of such materials in human food, including dietary supplements, and in cosmetics. FDA is taking this action in response to comments received on the interim final rule. Information was provided in comments that persuaded the agency that the distal ileum, one of three portions of the small intestine, could be consistently and effectively removed from the small intestine, such that the remainder of the small intestine, formerly a prohibited cattle material, could be used for human food or cosmetics. We (FDA) are also clarifying that milk and milk products, hide and hide-derived products, and tallow derivatives are not prohibited cattle materials. Comments also led the agency to reconsider the method cited in the interim final rule for determining insoluble impurities in tallow and to cite instead a method that is less costly to use and requires less specialized equipment. FDA issued the interim final rule to minimize human exposure to materials that scientific studies have demonstrated are highly likely to contain the bovine spongiform encephalopathy (BSE) agent in cattle infected with the disease. FDA believes that the amended provisions of the interim final rule provide the same level of protection from human exposure to the agent that causes BSE as the original provisions.